Works about ACUTE myeloid leukemia treatment
Results: 1228
Acute myeloid leukaemia: A guide for practice nurses.
- Published in:
- Practice Nursing, 2018, v. 29, n. 3, p. 123, doi. 10.12968/pnur.2018.29.3.123
- By:
- Publication type:
- Article
A retrospective review of acute myeloid leukaemia in 35 dogs diagnosed by a combination of morphologic findings, flow cytometric immunophenotyping and cytochemical staining results (2007‐2015).
- Published in:
- Veterinary & Comparative Oncology, 2018, v. 16, n. 2, p. 268, doi. 10.1111/vco.12377
- By:
- Publication type:
- Article
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis.
- Published in:
- Clinical & Experimental Nephrology, 2011, v. 15, n. 3, p. 434, doi. 10.1007/s10157-011-0405-5
- By:
- Publication type:
- Article
Cost-analysis of Treatment of Patients with Acute Myeloid Leukemia.
- Published in:
- International Journal of Cancer Management, 2021, v. 14, n. 8, p. 1, doi. 10.5812/ijcm.109172
- By:
- Publication type:
- Article
Contribution Value of Akt, c-Myc, CIP2A, and PP2A Genes Expression in Leukemogenesis: A Bright Perspective on the Molecular Pattern of Patients with Acute Myeloid Leukemia (AML).
- Published in:
- International Journal of Cancer Management, 2020, v. 13, n. 3, p. 1, doi. 10.5812/ijcm.100223
- By:
- Publication type:
- Article
Changes in pH and Sodium Salivary Bicarbonate Among Patients with Acute Myeloid Leukemia Before and After Chemotherapy.
- Published in:
- International Journal of Cancer Management, 2019, v. 12, n. 2, p. 1, doi. 10.5812/ijcm.83449
- By:
- Publication type:
- Article
Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 2, p. 1, doi. 10.1093/jnci/djt440
- By:
- Publication type:
- Article
Drug Shortages Delay Cancer Clinical Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 12, p. 891, doi. 10.1093/jnci/djs293
- By:
- Publication type:
- Article
Immunotherapy of Acute Myeloid Leukemia: Current Approaches.
- Published in:
- Oncologist, 2009, v. 14, n. 3, p. 240, doi. 10.1634/theoncologist.2008-0165
- By:
- Publication type:
- Article
Acute Myelogenous Leukemia in Older Adults.
- Published in:
- Oncologist, 2009, v. 14, n. 3, p. 222, doi. 10.1634/theoncologist.2008-0224
- By:
- Publication type:
- Article
Recent Developments in Acute Myelogenous Leukemia Therapy.
- Published in:
- Oncologist, 2007, v. 12, p. 14, doi. 10.1634/theoncologist.12-S2-14
- By:
- Publication type:
- Article
Innovative Approaches in the Treatment and Support of Patients with Acute Myelogenous Leukemia.
- Published in:
- Oncologist, 2007, v. 12, p. 1, doi. 10.1634/theoncologist.12-S2-1
- By:
- Publication type:
- Article
Case Study: Molecular Profiling in Acute Myeloid Leukemia.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 2, p. 86
- By:
- Publication type:
- Article
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Mayo Clinic experience with 1123 adults with acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00435-1
- By:
- Publication type:
- Article
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00433-3
- By:
- Publication type:
- Article
All-trans retinoic acid 45 mg/m2 is superior to 25 mg/m2 as the first induction regimen for the treatment of acute promyelocytic leukaemia: a retrospective analysis in a real-world clinical setting.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-021-00411-9
- By:
- Publication type:
- Article
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0316-3
- By:
- Publication type:
- Article
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0211-y
- By:
- Publication type:
- Article
A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00609
- By:
- Publication type:
- Article
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00405
- By:
- Publication type:
- Article
Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00432
- By:
- Publication type:
- Article
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00369
- By:
- Publication type:
- Article
Alloreactive natural killer cells for the treatment of acute myeloid leukemia: from stem cell transplantation to adoptive immunotherapy.
- Published in:
- Frontiers in Immunology, 2015, v. 6, p. 1, doi. 10.3389/fimmu.2015.00479
- By:
- Publication type:
- Article
Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 8, p. 1057, doi. 10.1038/bmt.2015.82
- By:
- Publication type:
- Article
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 8, p. 1063, doi. 10.1038/bmt.2015.121
- By:
- Publication type:
- Article
Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 7, p. 1004, doi. 10.1038/bmt.2015.62
- By:
- Publication type:
- Article
Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 7, p. 907, doi. 10.1038/bmt.2015.59
- By:
- Publication type:
- Article
Minimal antileukaemic treatment followed by reduced-intensity conditioning in three consecutive children with Fanconi anaemia and AML.
- Published in:
- Bone Marrow Transplantation, 2015, v. 50, n. 3, p. 463, doi. 10.1038/bmt.2014.283
- By:
- Publication type:
- Article
Recombinant human keratinocyte growth factor: successful treatment of severe, refractory hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 12, p. 1550, doi. 10.1038/bmt.2014.205
- By:
- Publication type:
- Article
Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 5, p. 679, doi. 10.1038/bmt.2014.9
- By:
- Publication type:
- Article
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 3, p. 389, doi. 10.1038/bmt.2013.204
- By:
- Publication type:
- Article
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 1, p. 11, doi. 10.1038/bmt.2013.121
- By:
- Publication type:
- Article
To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.
- Published in:
- Bone Marrow Transplantation, 2013, v. 48, n. 12, p. 1497, doi. 10.1038/bmt.2013.67
- By:
- Publication type:
- Article
Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation.
- Published in:
- Bone Marrow Transplantation, 2013, v. 48, n. 7, p. 994, doi. 10.1038/bmt.2012.256
- By:
- Publication type:
- Article
Yellow fever vaccine viremia following ablative BM suppression in AML.
- Published in:
- Bone Marrow Transplantation, 2013, v. 48, n. 7, p. 1008, doi. 10.1038/bmt.2012.277
- By:
- Publication type:
- Article
Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.
- Published in:
- Bone Marrow Transplantation, 2012, v. 47, n. 12, p. 1535, doi. 10.1038/bmt.2012.88
- By:
- Publication type:
- Article
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
- Published in:
- Bone Marrow Transplantation, 2012, v. 47, n. 9, p. 1171, doi. 10.1038/bmt.2011.242
- By:
- Publication type:
- Article
Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
- Published in:
- Bone Marrow Transplantation, 2012, v. 47, n. 7, p. 1008, doi. 10.1038/bmt.2011.210
- By:
- Publication type:
- Article
Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.
- Published in:
- Bone Marrow Transplantation, 2012, v. 47, n. 7, p. 924, doi. 10.1038/bmt.2011.195
- By:
- Publication type:
- Article
Physicians Oral AbstractsEBMT 2012.
- Published in:
- Bone Marrow Transplantation, 2012, v. 47, p. S1, doi. 10.1038/bmt.2012.36
- Publication type:
- Article
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
- Published in:
- Bone Marrow Transplantation, 2011, v. 46, n. 5, p. 641, doi. 10.1038/bmt.2010.190
- By:
- Publication type:
- Article
High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR.
- Published in:
- Bone Marrow Transplantation, 2011, v. 46, n. 3, p. 385, doi. 10.1038/bmt.2010.115
- By:
- Publication type:
- Article
Management of relapse after allo-SCT for AML and the role of second transplantation.
- Published in:
- Bone Marrow Transplantation, 2009, v. 44, n. 12, p. 769, doi. 10.1038/bmt.2009.300
- By:
- Publication type:
- Article
Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis.
- Published in:
- Bone Marrow Transplantation, 2009, v. 44, n. 4, p. 269, doi. 10.1038/bmt.2009.17
- By:
- Publication type:
- Article
The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies.
- Published in:
- Bone Marrow Transplantation, 2009, v. 43, n. 4, p. 275, doi. 10.1038/bmt.2009.7
- By:
- Publication type:
- Article
Treatment of adult AML with t(6;11)(q27;q23) by allogeneic hematopoietic SCT in the first CR.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
- Published in:
- Bone Marrow Transplantation, 2008, v. 42, n. 3, p. 145, doi. 10.1038/bmt.2008.185
- By:
- Publication type:
- Article